<DOC>
	<DOCNO>NCT02804360</DOCNO>
	<brief_summary>Purpose : Cystoid macular edema ( CME ) retinitis pigmentosa ( RP ) manage several way little success . The aim study report use intravitreal dexamethasone implant large series patient RP CME . Setting : Retrospective case series . Methods : Cases diagnose RP base classic fundus triad bone-spicule pigment deposit ( intraretinal pigmentary migration ) , retinal vessel attenuation , waxy pallor optic disc along night blindness attenuate ERG amplitude ( delay rod cone b-wave implicit time ) . Family history RP family screen RP important establish diagnosis eye diagnostic challenge . CME diagnose intravitreous fluorescein angiography IVFA spectral domain optical coherence tomography ( SD-OCT ) . BCVA monitor use Snellen visual acuity chart CME monitor SD-OCT follow-up visit .</brief_summary>
	<brief_title>Intravitreal Dexamethasone Implant Retinitis Pigmentosa-related Macular Edema- Retrospective Study</brief_title>
	<detailed_description>Introduction Retinitis pigmentosa ( RP ) group inherit progressive retinal degeneration characterize photoreceptor dysfunction primarily affect rod , follow cone worldwide prevalence approximately one 3,000-4,000 total 2 million affected individual world . After rod die , cone photoreceptors gradually die result constriction visual field eventual blindness many patient . There presently cure RP photoreceptor apoptosis play key role , considerable effort devote search rescue strategy . This condition lead blindness advance stage disease , involve central retina . Also macular abnormality appear frequently RP lead visual decline . CME prevalent 20-70 % RP patient several treatment option report variable success rate many side-effects . Therapies include oral topical carbonic anhydrase inhibitor , intravitreal VEGF antagonist , periocular intravitreal corticosteroid . The dexamethasone implant recently approve treatment maculopathies relate diabetic retinopathy retinal vein occlusion uveitis . The current study explores role implant CME RP . Methods The investigator conduct retrospective noncomparative study use intravitreal dexamethasone implant eye CME RP . The study adhere tenet declaration Helsinki . All patient sign informed consent detail review benefit complication current therapy . RP define presence triad bone-spicule pigment deposit , retinal vessel attenuation waxy pallor optic disc . Family history RP , family screen RP , ERG record ancillary test atypical RP . CME define presence cystoid change macula see linear scan spectral domain OCT regardless presence retinal thickening ( Gorovoy ) . Primary outcome best-corrected visual acuity central macular thickness . Study duration January 2012 ? ? December 2015 participant sign formal consent . Inclusion criterion include naïve previously treat CME . Exclusion criterion include diabetes mellitus , vitreous hemorrhage , macular ischemia , macular scar subretinal fibrosis , corneal scar , infectious conjunctivitis , prior cataract vitreous surgery , inability commit long-term follow-up . Primary outcome measure include best-corrected visual acuity ( BCVA ) assess Snellen chart central macular thickness ( CMT , mean thickness central 1000-μm diameter area ) use spectral domain optical coherence tomography ( OCT ) . Intravenous fluorescein angiography do initial exam use standard protocol visualization retinal midperiphery . Comprehensive ocular examination include applanation tonometry perform baseline , usually month 1 , month 2 month 3 thereafter . Ozurdex® ( Allergan , Inc. , Irvine , CA , USA ) intravitreal rod shape implant contain 0.7 mg dexamethasone Novadur® poly ( D , L-lactide-co-glycolide solid polymer sustained-release drug delivery system . The implant inject sterile condition use povidone iodine 5 % , sterile lid speculum topical anesthesia . Only one patient 9-year old receive sedative agent order achieve patient cooperation . The single-use applicator inject midvitreous self-sealing scleral injection 3,5 mm posterior limbus superotemporal inferotemporal area . Genetic test carry current case series . Statistical analysis do use SPSS version 22 ( IBM Corporation , Chicago , Illinois ) Wilcoxon-Signed Rank Test significance set p-value 0.05 .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Retinitis pigmentosa cystoid macular edema infection , inability consent , cataract , glaucoma , endstage retinitis pigmentosa</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>